Skip to main content
Bottles with blue caps)

Product Pipeline

Focused on Innovation

CSL is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people’s lives depend on it, CSL’s R&D fuels the company’s sustainable growth by advancing world-class science, technology and collaboration. Our strong R&D pipeline utilises its expertise in plasma protein technology, recombinant technology, cell and gene therapy and vaccines technology to develop and deliver innovative medicines that address unmet medical needs or enhance current treatments in six Therapeutic Areas - Immunology, Hematology, Respiratory, Cardiovascular and Metabolic, Transplant and Vaccines. Our R&D portfolio focuses on innovation in new products, improved products and manufacturing expertise ensuring our continued growth.

Core Capabilities

as demonstrated in our product pipeline 

Phase I

Phase II

Phase III

Registration / Post-Registration

R&D Portfolio
Phase II

HIZENTRA® (SSc)

20% subcutaneous immunoglobulin, for the treatment of Systemic Sclerosis (SSc).

TS23 α2AP mAb (sPE)

Anti-α2-antiplasmin monoclonal antibody, which is being developed to dissolve thrombi that cause serious conditions such as submassive pulmonary embolism (sPE) and acute ischemic stroke (AIS).

Garadacimab Anti-FXIIa mAb (ILD/IPF)

A humanised anti-FXIIa monoclonal antibody for the potential treatment of Interstitial Lung Diseases (ILD) and Idiopathic Pulmonary Fibrosis (IPF).

Clazakizumab Anti-IL-6 mAb (ESKD)

Humanized recombinant monoclonal antibody targeting interleukin-6 (IL-6) for the potential treatment of end stage kidney disease (ESKD) in patients undergoing dialysis .

Adjuvanted Cell Culture Influenza Vaccine (aQIVc)

Adjuvanted Cell Culture Influenza Vaccine (aQIVc) combines FLUCELVAX® antigen with MF59® adjuvant (an additive that acts to strengthen the immune response to vaccination) to protect against four seasonal strains of influenza.

Mavrilimumab Anti-GM-CSFR mAb (GCA, COVID)*

Recombinant monoclonal antibody against the granulocyte macrophage colony-stimulating factor receptor as a potential treatment for inflammatory diseases such as Giant Cell Arthritis (GCA & COVID-19).
*Licensed to Kiniksa Pharmaceuticals.

Eblasakimab (CSL334) Anti-IL-13R mAb (AD)*

Monoclonal antibody targeting IL-13Rα1 for the treatment of atopic dermatitis (AD) and asthma.
*Licensed to ASLAN Pharmaceuticals.

VAMIFEPORT Ferroportin inhibitor (SCD)

Oral ferroportin inhibitor for treatment of beta-thalassemia and Sickle Cell Disease (SCD).

Phase III

Garadacimab Anti-FXIIa mAb (HAE)

Humanised anti-factor XIIa monoclonal antibody for the potential treatment of Hereditary Angioedema (HAE) by subcutaneous administration.

HIZENTRA® (DM)

20% subcutaneous immunoglobulin for the treatment and long-term maintenance therapy of adults with Dermatomyositis (DM).

KCENTRA® 4F-PCC (Trauma)

A 4-factor prothrombin complex concentrate (4F-PCC) for the potential treatment of massive hemorrhage associated with severe traumatic injury.

CSL112 apoA-I (AMI)

Novel apolipoprotein A-I infusion therapy to potentially reduce the risk of major adverse cardiovascular events (MACE) in patients with myocardial infarction (AMI).

Clazakizumab Anti-IL-6 mAb (AMR)

Humanized recombinant monoclonal antibody targeting interleukin-6 (IL-6) for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading cause of long-term rejection in kidney transplant recipients.

CSL964 Alpha-1 Antitrypsin (Prevention of GvHD)

Prevention of acute Graft-versus-Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).

CSL964 Alpha-1 Antitrypsin (Treatment of GvHD)*

Treatment of steroid refractory, acute Graft-versus-Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).
*In collaboration with Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

ARCT-154* COVID-19 Vaccine

mRNA vaccine is being developed for the prevention of COVID-19 infections.
* Transaction with Arcturus Therapeutics is subject to customary regulatory clearances before closing

INJECTAFER® Ferric carboxymaltose (HF-ID)

High dose intravenous iron (ferric carboxymaltose) for the treatment of iron deficiency in heart failure patients.

Sparsentan Dual ETA & AT1 antagonist (FSGS)

High affinity, dual-acting antagonist of endothelin type A (ETA) & angiotensin type 1 (AT1) for treatment of focal segmental glomerulosclerosis (FSGS).

Sparsentan Dual ETA & AT1 antagonist (IgAN)

High affinity, dual-acting antagonist of endothelin type A (ETA) & angiotensin type 1 (AT1) for treatment of immunoglobulin A neuropathy (IgAN).

SNF472 Calcification inhibitor (CUA-ESKD)

Calcification inhibitor for treatment of calcific uremic arteriolopathy (CUA) in patients with end-stage kidney disease (ESKD).

SNF472 Calcification inhibitor (PAD-ESKD)

Calcification inhibitor for treatment of Peripheral Artery Disease (PAD) in patients with end-stage kidney disease (ESKD).

Registration / Post-Registration

HAEGARDA® (HAE)

Self-administered, subcutaneous C1-esterase inhibitor (human) for routine prophylaxis to prevent HAE attacks.

HIZENTRA® (SCIg) 20% Liquid

20% subcutaneous immunoglobulin.

PRIVIGEN® (IVIg) 10% Liquid

10% intravenous immunoglobulin.

AFSTYLA® rFVIII (Hem A)

Novel, recombinant factor VIII product for the treatment of adults and children with hemophilia A.

IDELVION® rFIX-FP (Hem B)

Novel, long-acting recombinant factor IX product for the treatment of hemophilia B.

Etranacogene dezaparvovec (Hem B)

Recombinant adeno-associated viral vector of serotype 5 (AAV5) gene therapy containing the Padua variant of a codon-optimized human FIX complementary deoxyribonucleic acid (AAV5-Padua hFIX) for the treatment of Hemophilia B.

ZEMAIRA®/RESPREEZA® Alpha-1 Antitrypsin

Alpha-1 Proteinase Inhibitor (Human) for treatment of Alpha-1 Antitrypsin (AAT) Deficiency.

FOCLIVIA®/AFLUNOV® Adjuvanted Egg-based Influenza A (H5N1) Vaccine

Pre-pandemic, egg-based vaccine combined with CSL Seqirus' proprietary adjuvant, MF59® (an additive that acts to strengthen the immune response to vaccination), to protect against influenza A (H5N1) - the 'bird-flu' strain.

AUDENZTM Adjuvanted Monovalent Influenza A (H5N1) Vaccine

Pre-pandemic, cell-based vaccine combined with CSL Seqirus' proprietary adjuvant, MF59® (an additive that acts to strengthen the immune response to vaccination), to protect against influenza A (H5N1) - the 'bird-flu' strain.

AFLURIA® QUAD Egg-based Influenza Vaccine

Seasonal egg-based, split virion quadrivalent influenza vaccine registered in the US and Australia for use in children 6 months of age and older.

FLUAD® Trivalent Adjuvanted Influenza Vaccine

Seasonal, egg-based trivalent vaccine combined with Seqirus' proprietary adjuvant, MF59® (an additive that acts to strengthen the immune response to vaccination) to protect against three different strains of influenza.

FLUAD® Quadrivalent Adjuvanted Influenza Vaccine

Seasonal, egg-based quadrivalent vaccine, combined with CSL Seqirus' proprietary adjuvant, MF59® (an additive that acts to strengthen the immune response to vaccination) to protect against four different strains of influenza.

FLUCELVAX® Quadrivalent Cell-based Influenza Vaccine

Seasonal cell culture-based, quadrivalent influenza vaccine offering protection against four different strains for use in children 6 months of age and older.

PANVAX® Egg-based Influenza Vaccine

Pre-pandemic, egg-based vaccine to protect against influenza A (H1N1) - the 'swine-flu' strain.

FERINJECT® Ferric carboxymaltose (ID)

High dose intravenous iron (ferric carboxymaltose) for the treatment of iron deficiency and iron deficient anaemia, where oral iron is ineffective or cannot be used or when there is a clinical need to deliver iron rapidly.

KORSUVATM / KAPRUVIA® KOR agonist (CKD-aP)

Difelikefalin - a kappa-opioid receptor (KOR) agonist for treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adult patients on haemodialysis.

RAYALDEE® Oral ext. release calcifediol (SHPT)

Orally administered, prolonged-release formulation of calcifediol for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency or deficiency.

TAVNEOS® Oral C5a receptor inhibitor (AAV)

Orally administered, highly potent and selective inhibitor of C5aR1 (complement C5a receptor 1) for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (ANCA)-associated vasculitis (AAV).

VELPHORO® Sucroferric oxyhydroxide (Serum Phosporous control in CKD)

A non-calcium, iron-based phosphate binder used for the control of serum phosphorus levels in adults with chronic kidney disease (CKD) on haemodialysis or peritoneal dialysis.

VELTASSA® Oral potassium binder (HK)

A non-absorbed, oral potassium binder for the treatment of hyperkalemia.

*Indicates partnered projects